Recent Updates
Recently added Catalysts
SNTI Positive Sentiment

SENTI-202 CD33 OR FLT3 NOT EMCN Logic-Gated Gene Circuit Components Selectively Target AML while Protecting Human HSC/HPCs from Off-Tumor Toxicity in a Humanized Mouse Model

Wednesday, April 30, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses SENTI-202, a gene circuit technology designed to target Acute Myeloid Leukemia (AML) while minimizing toxicity to human hematopoietic stem and progenitor cells. The findings indicate that the logic-gated components of SENTI-202 selectively engage AML cells, showcasing its potential as a therapeutic option. This advancement could significantly enhance treatment safety and efficacy.
Price reaction · baseline $3.17 (2025-04-29 close) · hit pre-market · clean, no other SNTI news in the window
day 0 close · peak
+4.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • SENTI-202 shows promise in selectively targeting AML.
  • The approach protects human HSC/HPCs from off-tumor toxicity.
  • Utilizes innovative gene circuit technology.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
76.7%
average across 4 past catalysts
Cash runway
~5 mo
High dilution risk
Lead asset
SENTI-202
Phase 1 · AML/MDS

Full Press Release Details

• About Overview Team Board of Directors Scientific Advisory Board
• Approach Overview Gene Circuit Technology Platform
• Research & Pipeline Pipeline SENTI-202 for Acute Myeloid Leukemia Presentations & Publications Expanded Access to Investigational Medicines
• Investors Overview Press Releases Events and Presentations Analyst Coverage Financials and Filings Corporate Governance Documents and Charters Leadership Team Board of Directors Committee Composition Stock Information Investor Resources FAQ Email Alerts Contact Us
• Careers
• Overview
• Team
• Board of Directors
• Scientific Advisory Board
• Overview
• Gene Circuit Technology Platform
• Pipeline
• SENTI-202 for Acute Myeloid Leukemia
• Presentations & Publications
• Expanded Access to Investigational Medicines
• Overview
• Press Releases
• Events and Presentations
• Analyst Coverage
• Financials and Filings
• Corporate Governance Documents and Charters Leadership Team Board of Directors Committee Composition
• Stock Information
• Investor Resources FAQ Email Alerts Contact Us
• Documents and Charters
• Leadership Team
• Board of Directors
• Committee Composition
• FAQ
• Email Alerts
• Contact Us
AACR Annual Meeting Muharrem Muftuoglu, Mahesh Basyal, Li Li, Jiangxing Lv, Lauren Ostermann, Han Deng, Priscilla Wong, Timothy K. Lu, Brian S. Garrison, Kanya Rajangam, Michael Andreeff

View PDF

Frequently Asked Questions

What is SENTI-202?

SENTI-202 is a gene circuit technology aimed at targeting Acute Myeloid Leukemia.

How does SENTI-202 protect human HSCs?

It selectively targets AML cells while minimizing off-tumor toxicity to human hematopoietic stem cells.

What are the benefits of using SENTI-202?

The technology enhances treatment safety and efficacy by reducing toxicity to healthy cells.

What type of model was used in the study?

The study utilized a humanized mouse model to evaluate SENTI-202's effectiveness.

ShareAdd on Google
Tags: SNTI Viatris Investor Conferences Healthcare SENTI-202 Acute Myeloid Leukemia gene circuit technology HSC toxicity
Last updated: Apr 30, 2025

Biotech snapshot

Cash runway
$19M liquidity · $2M/mo burn
~5 mo
High dilution risk
Lead asset
SENTI-202Phase 1
AML/MDS →

Catalyst track record

+84%
best trade around SNTI's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for SNTI.

See every catalyst's timing & PoA →